Key regions: Germany, United States, India, Japan, United Kingdom
The demand for Anti-Rheumatic Drugs in Mozambique has seen a steady increase in recent years.
Customer preferences: Patients suffering from rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis are the primary customers of Anti-Rheumatic Drugs. These patients prefer drugs that can alleviate their symptoms and improve their quality of life. They also prefer drugs that are affordable and easily accessible.
Trends in the market: The Anti-Rheumatic Drugs market in Mozambique has witnessed a surge in demand due to the increasing prevalence of rheumatoid arthritis and other related diseases. The market is expected to continue growing due to the rising awareness of these diseases and the availability of new and innovative drugs. In addition, the government's efforts to improve healthcare infrastructure and access to medication have also contributed to the growth of the market.
Local special circumstances: Mozambique is a low-income country with a high burden of infectious diseases, such as HIV/AIDS, tuberculosis, and malaria. However, the rising prevalence of non-communicable diseases, including rheumatoid arthritis, has become a major concern for the government and healthcare providers. The lack of rheumatologists and specialized healthcare facilities in the country has led to a delay in the diagnosis and treatment of these diseases.
Underlying macroeconomic factors: The Mozambican economy has been growing steadily in recent years, driven by the development of the natural gas industry and increased foreign investment. However, the country still faces significant challenges, including high levels of poverty, inequality, and unemployment. The healthcare sector is also underfunded, with limited resources and infrastructure. The government has recognized the importance of improving healthcare and has increased its budget allocation for the sector in recent years. However, more needs to be done to address the growing burden of non-communicable diseases and improve access to specialized care and medication.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
